Background: In order to improve lung cancer survival in the UK, a greater proportion of resectable cancers must be diagnosed. It is likely that resectability rates would be increased by more timely diagnosis. Aside from screening, the only way of achieving this is to reduce the time to diagnosis in symptomatic cancers. Currently, lung cancers are mainly diagnosed by general practitioners (GPs) using the National Institute for Health and Clinical Excellence (NICE) guidelines for urgent referral for chest X-ray, which recommend urgent imaging or referral for patients who have one of a number of chest symptoms for more than 3 weeks. We are proposing to expand this recommendation to include one of a number of chest symptoms of any duratio...
Background The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility randomi...
Background: Despite increasing use of computed tomography (CT), chest X-ray remains the first-line i...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
Published onlineJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tBACKGROUND...
Background: In order to improve lung cancer survival in the UK, a greater proportion of resectable c...
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in th...
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in th...
Published onlineJournal ArticleThis is the author accepted manuscript. The final version is availabl...
BACKGROUND: Diagnostic capacity and suboptimal logistics are consistently identified as barriers to ...
BACKGROUND: Diagnostic capacity and suboptimal logistics are consistently identified as barriers t...
Background Chest X-ray (CXR) is the first-line investigation for lung cancer in many countries but p...
Lung cancer is a major global health burden with high incidence rates but poor long-term survival. C...
Background: The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility random...
Background: Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). E...
Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnos...
Background The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility randomi...
Background: Despite increasing use of computed tomography (CT), chest X-ray remains the first-line i...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...
Published onlineJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tBACKGROUND...
Background: In order to improve lung cancer survival in the UK, a greater proportion of resectable c...
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in th...
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in th...
Published onlineJournal ArticleThis is the author accepted manuscript. The final version is availabl...
BACKGROUND: Diagnostic capacity and suboptimal logistics are consistently identified as barriers to ...
BACKGROUND: Diagnostic capacity and suboptimal logistics are consistently identified as barriers t...
Background Chest X-ray (CXR) is the first-line investigation for lung cancer in many countries but p...
Lung cancer is a major global health burden with high incidence rates but poor long-term survival. C...
Background: The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility random...
Background: Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). E...
Lung cancer kills more people than any other cancer in the UK (5-year survival < 13%). Early diagnos...
Background The ELCID (Early Lung Cancer Investigation and Diagnosis) trial was a feasibility randomi...
Background: Despite increasing use of computed tomography (CT), chest X-ray remains the first-line i...
Funding for the study was provided by the Chief Scientist Office, Scottish Government and Oncimmune ...